Japan Exports to U.S. Rebound in November as Tariff Impact Eases, Boosting BOJ Rate Hike Expectations 
Oil Prices Rebound as U.S.-Venezuela Tensions Offset Oversupply Concerns 
NASA Faces Major Workforce Reduction as 20% of Employees Prepare to Leave 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Bolivia Orders Pre-Trial Detention of Former President Luis Arce Over Embezzlement Probe 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
New Epstein Photos Surface Showing Trump as Lawmakers Near Document Release Deadline 
U.S. Pressures ICC to Limit Authority as Washington Threatens New Sanctions 
EU Court Cuts Intel Antitrust Fine to €237 Million Amid Long-Running AMD Dispute 
Dollar Struggles as Markets Eye Key Central Bank Decisions and Global Rate Outlooks 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Gold and Silver Prices Dip as Markets Await Key U.S. Economic Data 
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure 
Gold and Silver Surge as Safe Haven Demand Rises on U.S. Economic Uncertainty 
The Seoul Central District Court had ruled that Medytox's patents for botulinum toxin (botox) strains and manufacturing process were stolen by Daewoong Pharmaceutical in developing Nabota.
Thus, the court prohibited Daewoong from manufacturing and selling its botox products, ordering that those that have already been produced should be discarded.
It also ordered Daewoong to pay 40 billion won in damages to Medytox, the first Korean company to succeed in mass-producing botox strains.
Medytox sued Daewoong in 2017, accusing it of stealing its botox strain and manufacturing process.
Daewoong claimed that it found its botox strain in a barn in Gyeonggi Province.
Medytox vowed to continue to protect its patent, while Daewoong said it would appeal the ruling.
The US International Trade Commission (USITC) had earlier ruled in favor of Medytox in December 2020 and ordered a 21-month import ban on Daewoong's products into the US. Daewoong also agreed to pay royalties to Medytox to settle the dispute shortly after the USITC decision.
